Data-driven weight management

The science of weight loss,
made personal

An independent GLP-1 safety database. Real data from clinical trials, patient experiences, and regulatory reports — free, with every source cited.

Explore the data Join the waitlist
2,197 data points
15 effects tracked
Updated daily

2,197

Data points

15

Effects tracked

9

Drugs covered

8

Data sources

Tools

Your personal journey

Side Effects Predictor

See your personalised risk profile for 15 side effects

Try it

Weight Trajectory

Predict your weight loss journey based on STEP trial data

Try it

Muscle Preservation

Assess your risk of muscle loss and get evidence-based recommendations

Try it

After Stopping

Understand what happens when you stop — and how to prepare

Try it
Trending

What's happening in GLP-1

UK GLP-1 grey market: 135 companies, 1 death — what patients need to know

Our Companies House audit: 98 brand-new shell companies, no credible GLP-1 supplier, and documented harm.

Read more

40+ generic semaglutides launched in India after March 2026 patent expiry

India's patent expiry opens the door for dozens of affordable generic versions.

Read more

CDSCO-approved generics bring weight management costs below ₹1,500/month

Registered generics make weight management accessible to millions.

Read more
How It Works

Four ways to use Magistra today

01

Explore the database

2,197 structured data points across 15 side effects and 9 medications — updated daily, sources cited.

02

Check your personal risk

The free predictor estimates your side-effect risks and weight trajectory from your profile.

03

Read the evidence

Clinical trials side by side with real-world reports, plus weekly market and pricing analysis by country.

04

Tell us what to track

Missing a side effect, drug, or data source? Your suggestions steer what we collect next.

Why Magistra

Three layers of safety, in one platform

Almost everything written about GLP-1 online comes from someone selling you something — the manufacturer, a clinic, or the grey market. We don't sell medication. We publish the data.

01

Independent, sells nothing

We don't prescribe, don't dispense, and earn nothing from your treatment — so our numbers have nothing to sell. Every data point carries its source: clinical trials, FDA FAERS, regulators, and patient reports. Methodology published in full.

Read the methodology
02

Data-powered predictions

An independent, fully cited GLP-1 safety and efficacy database — drawn from clinical trials, FDA FAERS, regulatory reports, and patient experiences. Personalised forecasts for weight loss, side effects, and muscle preservation, to take to your own doctor.

See your forecast
03

Global supply intelligence

Weekly-updated tracking of GLP-1 supply, demand, and pricing across major global markets — patent expiries, licensed generic launches, cross-market pricing, and what you can check yourself about a pack and its cold chain.

Explore the market
Blog

Latest articles

Science & Safety·9 min

GLP-1 and Constipation: the Label Says 24%, and the Placebo Arm Says 11%

The US semaglutide label puts constipation at 24% on Wegovy 2.4 mg against 11% on placebo, so nearly half the headline is the background rate. We read the placebo arm of every constipation source in our corpus that posts one — from an 8,803-patient cardiovascular trial to a 61-participant dose-ranging study — and in the weight-reduction trials the label itself pools, the drug-minus-placebo difference is 11 to 14 points every time. Here is every arm, its n, and why our own pooled 11.8% is not the Wegovy number.

Read
Science & Safety·7 min

GLP-1 and Vomiting: Why Trial Rates Run From 6.5% to 58%

Search "how common is vomiting on Ozempic" and every answer gives you one number with no source. Our own corpus held 15 distinct sources that state a vomiting rate on 10 September 2026 — fourteen trials and one review quoting a fifteenth — and they range from 6.5% (an 8,803-patient cardiovascular outcome trial) to 58% (a 6-person early-phase pharmacology study). Both are real. Here is every trial, its population, its n, and why the range is this wide rather than a defect in the data.

Read
Science & Safety·8 min

Does Semaglutide or Tirzepatide Cause Hair Loss? What the Trial Registries and the Label Actually Report

The US semaglutide label puts hair loss at 3% versus 1% on placebo, and says it was associated with weight reduction and reported several times more often in women than in men. The tirzepatide registry posts alopecia per arm at about 5% versus 1.1%, and as of 7 September 2026 those three arms are also our own database's first eligible clinical rates for the effect — here is every number, the arm and n it belongs to.

Read
For Researchers

For researchers and healthcare professionals

Access the GLP-1 Safety Database via our public API. Free for citations, subscription for bulk access.

Explore the API Contact us
API
curl magistra.health/api/data?q=overview
{
  "totalDataPoints": 2,197,
  "totalEffectsTracked": 15,
  "drugsTracked": ["semaglutide", "tirzepatide", "liraglutide", ...],
  "dataSources": [{ "source": "PubMed", "points": ... }, ...]
}

What you can do today

Magistra is a data source, not a clinic. Everything below is available right now, free and without an account.

See your risk profile

Side-effect risk, weight trajectory, muscle loss, and discontinuation outlook, fitted to your characteristics.

Explore the open database

2,197 data points, each carrying its source, with clinical and real-world rates kept separate.

Use the data in your own work

Free public API, citable dataset, and published methodology for researchers, analysts, and journalists.

Get notified about new data

The database grows daily. Leave your email and we'll write when a major dataset release or new finding lands. No sales, no medication.

See your personal GLP-1 side-effect risk

Free Predictor